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It was reported that C-reactive protein (CRP) levels increase in parallel with the progression of chronic liver
diseases, such as chronic hepatitis and liver cirrhosis. Inflammatory markers, such as high sensitive C-reactive
protein (hsCRP), ferritin, transferrin, albumin, alpha-1 acid glycoprotein (AAG), alpha-2 macroglobulin
(AMG), alpha-1 anti-trypsin (AAT) and lipoprotein a [Lp(a)] were measured in coronary artery disease
patients (CAD) and CAD patients with non-alcoholic steatohepatitis (NASH). In the present preliminary
study an attempt was made to study whether there is an increase in the levels of CRP in CAD patients
associated with NASH. CAD patients showed an increase in CRP and serum ferritin levels. In CAD patients
with NASH along with an increase in the levels of serum ferittin (pB0.001), the levels of serum AMG and
ceruloplasmin (CP) were also increased (pB0.01). The CAD patients with NASH had a higher proportion of
diabetes, hypertension and dyslipidaemia compared to CAD patients. But how this difference contributes to
the elevation in acute inflammatory markers particularly AMG and CP levels in CAD patients with NASH
cannot be explained. This study shows that a substantial number of CAD patients may be associated with
NASH. Non-invasive simple parameters that reflect the degree of inflammation and fibrosis of the liver in
patients with NASH would facilitate improved understanding and treatment of the disease. Further studies
may be necessary to evaluate the percentage of NASH patients progressing to CAD.
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T
he C-reactive protein (CRP) is an important test
for diagnosis and monitoring patients with in-
flammatory conditions, such as inflammatory
bowel disease, acute pancreatitis and hepatocellular
carcinoma (13). Since non-alcoholic steatohepatitis
(NASH) is an inflammatory condition of the liver, an
increased CRP level may be expected. Gupta et al. (2)
reported that the expression of CRP is upregulated in
alcohol-induced acute liver injury; and serial measure-
ments of serum CRP levels are useful in assessing the
clinical activity of alcoholic hepatitis. Recently, it was
reported that the CRP levels increase in parallel with the
progression of chronic liver diseases (CLDs), such as
chronic hepatitis and liver cirrhosis (4, 5). We investigated
whether there is an added increase in the levels of CRP in
coronary artery disease (CAD) patients associated with
NASH.
Methods
Patients were recruited from the cardiac centre of High
Tech Hospital, which is affiliated to Vinayaka Deemed
Medical University, Salem, Tamil Nadu, India. The study
was approved by the Ethics Review Board of the
Institution.
In this study, 68 consecutive non-cirrhotic patients with
clinical and biochemical diagnosis of CAD were taken.
Of these, 36 CAD patients diagnosed with CAD had a
mean age of 42.894.6 years. These patients had no
history of alcohol intake or other liver diseases. Thirty-
two patients with a mean age of 55.995.6 years were
diagnosed to have CAD with non-alcoholic fatty liver
disease (NAFLD). The diagnosis was based on ultra-
sonographic diagnosis along with the estimations of
aspartate amino transferase (AST) and alanine amino
transferase (ALT) (AST/ALT ratioB1). Out of these 32
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biopsy. Twenty-eight age-matched controls were included
in the study.
Fasting blood glucose and two-hour post-prandial
glucose levels were measured to diagnose diabetes melli-
tus (ADA, American Diabetes Association criteria) at
baseline and at every three-month follow-up during the
study period. In these patients, liver disease was excluded
by performing liver function tests and imaging studies. In
all patients, the following parameters were evaluated: age,
sex, family history (DM or CLD), presence of vascular
disease (hypertension, ischaemic heart disease, cerebro-
vascular disease and peripheral vascular disease), pre-
sence of obesity, presence of central obesity (waist
circumference, waist:hip ratio), dyslipidaemia (total cho-
lesterol [ULN  upper limit of normal  200 mg/dl], HDL
cholesterol [ULN 60 mg/dl], LDL cholesterol [ULN 100
mg/dl], triglyceride [ULN 150 mg/dl], Apo-A1 lipoprotein
[normal range: 120176 mg/dl], Apo-B lipoprotein [nor-
mal range: 63114 mg/dl], lipoprotein-a [normal range:
up to 30 mg/dl]), hyperuricemia (uric acid level [ULN 7.2
mg/dl]).
Diabetes was diagnosed on the basis of the use of
insulin and/or oral hypoglycemic drugs, fasting plasma
glucose level 126 mg/dl and/or two-hour plasma
glucose level 200 mg/dl. Hyperlipidaemia was
diagnosed when fasting lipid values were above the 95th
percentile of the normal range on at least two occasions.
Hypolipoproteinemia was diagnosed when lipoprotein
Apo-A1 and Apo-B levels were below 95th percentile of
the normal range. Hypertension was defined as systolic
blood pressure 140 mm Hg and/or diastolic blood
pressure 90 mm Hg. Obesity was defined as body mass
index (BMI) 25 kg/m
2. Central obesity was defined in
males as waist circumference 90 cm or waist-to-hip
ratio 0.9 and in females as waist circumference 80 cm
or waist-to-hip ratio 0.85.
Acute inflammatory markers: high sensitive C-reactive
protein (hsCRP), ferritin, transferrin, albumin, alpha-1
acid glycoprotein (AAG), alpha2 macroglobulin (AMG),
alpha 1 anti trypsin (AAT) and Lipoprotein(a) (Lp(a)
were measured using standard methods.
Statistical analysis was performed using ANOVA.
p-Value was considered statistically significant if it
wasB0.05.
Results
Table 1 describes the clinical and laboratory character-
istics of patients with CAD, CAD patients with NASH
and controls. Levels of hs CRP were increased signifi-
cantly in patients with CAD associated with NASH
(pB0.0001) compared to control subjects (Table 3).
CAD patients showed an increase in CRP and serum
ferritin levels (Table 2). The levels of serum ferritin were
also elevated (pB0.001), but along with an increase in Table 1. Clinical and laboratory characteristics of patients









Gender (M/F) 24/12 10/8 18/10


















AST(U/L) 25933 5 922 0 91
ALT(U/L) 24946 8 982 1 91




Albumin (g/dl) 4.8590.14 4.6590.15 4.2090.15
aRefers to number of patients.
Note: AST, aspartate amino transferase; ALT, alanine amino
transferase; values are means9standard deviation.
Table 2. Serum acute phase protein levels in patients with






CRP (mg/dl) 4.7590.18 1.6890.28 B0.0001
Ferritin (ng/ml) 93.12965.52 81.25955.20 B0.001
Transferrin (mg/dl) 299.80944.55 275.45944.4 NS
Albumin (g/dl) 4.4090.28 4.7290.29 NS
AAG (mg/dl) 92.520.65 93.2022.05 NS







AAT (mg/dl) 169.64945.80 161.06946.48 NS
Lp(a) (mg/dl) 13.0699.61 12.019.50 NS
Note: CRP, C-reactive protein; AAG-alpha-1, acid glycoprotein;
AMG, alpha 2 macroglobulin; AAT, alpha-1 anti-trypsin; Lp(a),
lipoprotein a; CAD, coronary artery disease; NASH, non-alcoholic
steatohepatitis; NS, not significant; values are means9standard
deviation.
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(Table 3).
Discussion
Levels of CRP are elevated in inflammatory conditions,
including CAD. We found that the serum concentrations
of CRP in CAD patients with NASH were significantly
increased compared to control subjects. The level of this
acute inflammatory marker did not show any significant
difference between CAD patients and CAD patients with
NASH. Isolated and non-specific increases in serum
ferritin levels are frequently found in the absence of
iron overload and are associated with inflammation, liver
necrosis and alcohol abuse (6). Bacon et al. (6) reported
abnormal results of serum transferrin and ferritin levels
in patients with NASH, but none of their patients had
histologic evidence of hemochromatosis.
Subsequent studies of patients with NASH have shown
increased serum ferritin levels in 5362% of patients and
elevated transferrin saturation in 1122% (7, 8). A high
serum ferritin level associated with increased liver iron
concentration but normal transferrin saturation is typical
of a polymetabolic syndrome. A French group has
suggested it as a new iron overload entity, possibly
related to the insulin resistance syndrome (9, 10). Fargion
et al. (10) documented that hyperferritinaemia with
normal transferrin saturation is a hallmark of glucose
or lipid metabolism disorder and that patients with
increased serum ferritin, normal transferrin saturation,
a mild iron overload and multiple coexisting metabolic
alterations are at high risk of developing NASH. In
addition, they observed no correlation between liver iron
concentration and histological grade, and stage within a
group of patients with NASH. The findings in our study
of high serum ferritin and normal transferrin saturation
in patients with NASH are in agreement with the results
of previous studies. The increase in ferritin level may be
due to a synergistic induction of synthesis due to
increased iron stores and steatohepatitis. It is also
possible that an increase in ferritin occurs as a result of
acute phase response.
As a new finding, we observed increased serum
ceruloplasmin (CP) and AMG levels in patients with
NASH. The importance of this as a part of acute phase
reaction is unclear. CP exhibits oxidase activity. Also,
oxidation of Fe
2 to Fe
3, catalysed by CP, may be
important for the binding of iron to transferrin. Increased
serum CP concentration in CAD patients with NAFLD
may be due to high serum ferritin levels with normal
transferrin saturation (11).
There have been several reports that the serum
concentrations of acute phase proteins (APP) with high
sialic content (Lp(a), AAG, Haptoglobin (Hp) and AAT)
show variations in post menopausal women on hormone
replacement therapy (12). Min et al. (13) suggested that
although there was no difference between the serum
concentration of both Lp(a) and APR in patients with
hypoalbuminaemia and those with normoalbuminaemia,
there were significant differences in the serum AAT and
Hp concentrations.
Normal serum concentrations of Lp(a), AAG, Hpt and
AAT in our patients could be explained by different
kinetics of acute phase reactants or a different time of
increase or decrease. Also, these substances may not have
a role in the pathogenesis of NASH.
In conclusion, increased serum CRP, ferritin, CP and
AMG concentrations were observed in patients with
CAD associated with NASH. The CAD patients with
NASH had a higher proportion of diabetes, hypertension
and dyslipidaemia than CAD patients without NASH.
But how this difference contributes to the elevation of
acute inflammatory markers, particularly AMG and CP,
in CAD patients with NASH cannot be explained. We
show that a substantial number of CAD patients may be
associated with NAFLD and NASH. Non-invasive
simple parameters that reflect the degree of inflammation
and fibrosis of the liver in patients with NASH would
facilitate improved understanding and treatment of the
disease. Further studies may be necessary to evaluate the
percentage of NASH patients progressing to CAD.
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Table 3. Serum acute phase protein levels in coronary artery






CRP (mg/dl) 5.2690.16 1.6890.28 B0.0001
Ferritin (ng/ml) 168.33958.20 81.25955.20 B0.001
Transferrin (mg/dl) 302.0946.5 275.45944.4 NS
Albumin (g/dl) 4.1290.22 4.7290.29 NS
AAG (mg/dl) 89.05921.5 93.20922.05 NS







AAT (mg/dl) 165.05946.38 161.06946.48 NS
Lp(a) (mg/dl) 13.5697.66 12.0197.50 NS
Note: CRP, C-reactive protein; AAG-alpha-1, acid glycoprotein;
AMG, alpha-2 macroglobulin; AAT, alpha-1 anti trypsin; Lp(a),
lipoprotein a; CAD, coronary artery disease; NASH, non-alcoholic
steatohepatitis; NS, not significant; values are means9standard
deviation standard error.
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